Meta Analysis Of The Efficacy Of Fuzheng Huayu Capsule Combined With Entecavir In The Treatment Of Chronic Hepatitis B Liver Fibrosis

Purpose:To study the efficacy of Fuzhenghuayu Capsules combined with Entecavir in the treatment of liver fibrosis in chronic hepatitis B,and to provide treatment ideas and objective basis for delaying or reversing the progress of liver fibrosisMethods:Computer search of China National Knowledge Infrastructure Database(CNKI),Wanfang Database,Chongqing VIP Chinese Science and Technology Periodical Database(VIP),Chinese Biomedical Literature Database(CBM),PubMed,Cochrane,Chinese Clinical Registry,American Clinical Registry,and other Chinese and foreign databases.Randomized controlled clinical trials were performed to retrieve the clinical data of Fuzhenghuayu Capsule and Entecavir in the treatment of liver fibrosis since the establishment of the database until May 2019 Randomized controlled trials(Randomized Controlled Trials,RCTs),literature screening,data extraction and quality evaluation in accordance with the Jadad scale.A total of 14 literatures met the inclusion criteria,including 1886 patients with chronic hepatitis B fibrosis.Meta-analysis was performed using RevMan5.3 software and STATE 15 software The main indicators were liver fibrosis indicators[laminin(LN),hyaluronic acid(HA),type III procollagen(PC-III),type IV collagen(C-?),liver stiffness measurement(LSM),liver Fibrosis stage,liver inflammation grade];imaging indicators(inner diameter of portal vein,spleen thickness).The secondary indicators were liver function indicators[glutamin transaminase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),albumin(ALB)];HBV DNA negative rateResults:After strict screening,a total of 14 literatures were included in this meta-analysis.A total of 1886 patients with chronic hepatitis B liver fibrosis were included,of which 949 were in the experimental group and were treated with Fuzhenghuayu Capsules combined with entecavir,937 were in the controlled group and were treated with entecavir monotherapy.The meta-analysis of the outcome indicators showed the followingIndicators of liver fibrosis:Fuzhenghuayu capsule combined with entecavir is significantly better than entecavir monotherapy in reducing LN,HA,PC-?,C-?,LSM,and liver fibrosis stage,but there was no significant difference in the classification of liver inflammation Imaging indicators:The results show that Fuzhenghuayu Capsule combined with entecavir has a significant advantage over entecavir monotherapy in reducing the inner diameter of the portal vein and spleen thicknessLiver function indicators:The results show that Fuzhenghuayu Capsules combined with entecavir have significant advantages over entecavir alone in improving ALT,TBIL and ALB,But there is no significant difference in reducing ASTHBV DNA conversion rate:The results showed that Fuzhenghuayu Capsule combined with entecavir had no significant difference with entecavir monotherapyConclusionAccording to the 14 literatures finally included,meta-analysis confirmed that Fuzhenghuayu Capsule combined with entecavir has a significant advantage in improving liver fibrosis index,liver imaging index,and liver function index compared with entecavir monotherapy.